NVS has been the subject of a number of other research reports. Zacks Investment Research downgraded Novartis AG from a hold rating to a sell rating in a report on Wednesday, September 21st. JPMorgan Chase & Co. reiterated a buy rating on shares of Novartis AG in a report on Tuesday, July 19th. Chardan Capital decreased their price objective on Novartis AG from $95.00 to $92.00 and set a buy rating for the company in a report on Monday, October 10th. TheStreet upgraded Novartis AG from a hold rating to a buy rating in a report on Friday, June 24th. Finally, Argus reiterated a hold rating on shares of Novartis AG in a report on Thursday, August 25th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Hold and a consensus price target of $91.33.
Shares of Novartis AG (NYSE:NVS) opened at 76.09 on Friday. Novartis AG has a 1-year low of $69.90 and a 1-year high of $94.63. The stock’s 50 day moving average price is $79.33 and its 200-day moving average price is $78.96. The company has a market capitalization of $181.19 billion, a PE ratio of 27.17 and a beta of 0.57.
Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, July 19th. The company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.05. The company earned $12.47 billion during the quarter, compared to the consensus estimate of $12.33 billion. Novartis AG had a return on equity of 15.33% and a net margin of 13.84%. During the same quarter in the prior year, the company earned $1.25 earnings per share. On average, equities analysts predict that Novartis AG will post $4.72 EPS for the current year.
Several large investors have recently added to or reduced their stakes in NVS. OLD Mission Capital LLC boosted its stake in Novartis AG by 20.3% in the first quarter. OLD Mission Capital LLC now owns 142,568 shares of the company’s stock valued at $10,328,000 after buying an additional 24,099 shares during the period. Simmons Bank acquired a new stake in Novartis AG during the first quarter valued at approximately $1,143,000. Kimelman & Baird LLC boosted its stake in Novartis AG by 9.3% in the first quarter. Kimelman & Baird LLC now owns 94,210 shares of the company’s stock valued at $6,824,000 after buying an additional 8,050 shares during the period. Fairfield Bush & CO. boosted its stake in Novartis AG by 109.2% in the first quarter. Fairfield Bush & CO. now owns 100,439 shares of the company’s stock valued at $7,276,000 after buying an additional 52,425 shares during the period. Finally, Loomis Sayles & Co. L P boosted its stake in Novartis AG by 8.5% in the first quarter. Loomis Sayles & Co. L P now owns 5,242,948 shares of the company’s stock valued at $379,800,000 after buying an additional 408,972 shares during the period. 9.78% of the stock is currently owned by institutional investors.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.